This project focuses on understanding the biologic basis of advanced ovarian cancer. Specifically, Dr. Osman will study whether the aggressiveness of advanced ovarian cancer and its resistance to current drug therapies are associated with increased activity of a factor known as Hypoxia-inducible factor 1alpha (HIF-1α). Tissues from patients will be tested to determine the levels of HIF-1α within the ovarian cancer compared to adjacent normal tissues. Findings may lead to a new prognostic marker of advanced ovarian cancer and a potential therapeutic target in the treatment of advanced disease.
This grant is awarded in memory of Madeline Kahn and has been made possible by loving contributions in her memory, and with additional generous support from The Kaleidoscope of Hope Foundation.